Immunovant 股票：风险回报比极具吸引力，给予“投机性买入”评级 (IMVT)
· seekingalpha.com
基于 IMVT-1402 同类领先的 IgG 降低效果及约 40 亿美元的峰值销售前景，对 Immunovant (IMVT) 启动覆盖，给予“买入”评级，目标价 50 美元。详情见下文。
Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU ...